Anupam Rasayan India Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025, following a board meeting held on February 14, 2026. The specialty chemicals manufacturer released comprehensive standalone and consolidated financial statements under Regulation 33 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Exceptional Q3 FY26 Performance

The company demonstrated remarkable growth in the third quarter, with standalone revenue from operations reaching ₹4,013.67 million, representing an outstanding 89% year-on-year increase. Total revenue including other income stood at ₹4,063.20 million for the quarter.

Nine-Month Performance Highlights

The nine-month performance showed exceptional momentum across standalone operations. Revenue from operations for the nine months reached ₹13,049.87 million with remarkable 130% year-on-year growth, while profit after tax surged to ₹1,190.13 million, marking a substantial 244% increase.

Consolidated Financial Performance

On a consolidated basis, the company maintained strong growth trajectory with revenue from operations of ₹5,124.47 million in Q3 FY26 compared to ₹3,901.40 million in the previous year. Consolidated profit after tax reached ₹605.93 million for the quarter, while nine-month consolidated revenue touched ₹17,296.72 million.

Management Insights from Earnings Call

During the earnings call held on February 14, 2026, Managing Director Anand Desai highlighted the strong performance driven by scale-up of commercial molecules and improved capacity utilization. The company's revenue mix is well diversified across Agro, Pharma, Personal Care, and Performance Material segments, with Pharma contributing 19% of sales for 9M FY26.

Strategic Acquisition and Expansion

The company announced a definitive agreement to acquire 100% equity in Jayhawk Fine Chemicals, a US-based specialty chemicals company from the CABB Group. This acquisition will provide direct onshore manufacturing presence in the US, enhancing engagement with multinational customers and access to high-value markets including semiconductors, automotive, EV, Pharma, aviation, and electronics.

Pipeline and Development Focus

Chief Executive Officer Gopal Agrawal emphasized the company's strong pipeline with 65 plus molecules across R&D and pilot stages. The Pharma segment alone has more than 30 molecules under development, while the Polymer and Electronic Material vertical has 35 plus molecules in various stages of development.

Regulatory Compliance and Documentation

The financial results were prepared in accordance with Indian Accounting Standard 34 (Ind AS 34) for Interim Financial Reporting under Section 133 of the Companies Act, 2013. The earnings call transcript was submitted to stock exchanges under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, and is available on the company website at www.anupamrasayan.com .

Anupam Rasayan India Limited has executed comprehensive credit facilities totaling USD 50,000,000 on February 14, 2026, following the successful completion of its strategic Luxembourg acquisitions. The company disclosed the execution of multiple financing agreements and security arrangements under Regulation 30 of SEBI Listing Regulations.

Luxembourg Acquisition Completion

The company has successfully completed its overseas expansion through two key acquisitions in Luxembourg:

Doriath S.à r.l., registered under Luxembourg Trade and Companies Register number B300157, was incorporated on September 29, 2025. Batam S.à r.l., registered under number B301756, was incorporated on November 14, 2025. Both entities will focus on consultancy services and are registered at 9, rue de Bitbourg, L-1273 Luxembourg.

Credit Facility Execution Details

On February 14, 2026, the company executed two major credit facilities to support the acquisitions:

The Credit Facilities will be utilized to fund the partial consideration for Doriath's acquisition of 100% share capital in Monitchem Kansas S.à r.l. and an intragroup loan receivable. The ECB Facility proceeds will support Overseas Direct Investment in Doriath through a loan not exceeding USD 20,000,000.

Comprehensive Security Framework

The financing arrangements involve extensive security measures and corporate guarantees:

Catalyst Trusteeship Limited has been appointed as the onshore security trustee for the Credit Facilities, while Axis Trustee Services Limited serves as the security agent for the ECB Facility.

Strategic Investment Structure

Batam has agreed to invest USD 110,000,001 into Doriath pursuant to a share subscription agreement dated February 12, 2026. The investment proceeds will be used by Doriath to partially fund the acquisition of 100% share capital in Monitchem Kansas S.à r.l. and an intragroup loan receivable, in accordance with the Sale and Purchase Agreement dated December 9, 2025, with CABB Europe GmbH.

The transactions with Doriath constitute related party transactions as it is a wholly-owned subsidiary, while the company maintains no shareholding in Altis XII Pte. Ltd. or Catalyst Trusteeship Limited. All related party transactions are conducted on an arm's length basis, with the company receiving guarantee fees and commissions for issuing corporate guarantees.

Source: